Abstract
Since the 4th Triennial Conference at Antiviral Chemotherapy held in November 1994, no new antiviral drugs or vaccines have been approved for use in influenza or rhi-novirus infections in the United States. The only newly approved therapy for symptomatic management of upper respiratory illnesses is topical ipratropium. Intranasal administration of this quaternary anticholinergic reduces colds-associated rhinorrhea to a moderate extent.1 However, considerable clinical investigation has led to important advances in regard to prevention and treatment of influenza virus infections and provided new insights in regard to possible measures for management of rhinovirus infections. This paper will update previous reviews from this conference2,3,4,5 and summarize recent developments with agents that are in active clinical development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
